RVLPQ — RVL Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- $38.61m
- $49.72m
Annual income statement for RVL Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 264 | 240 | 178 | 17.5 | 49.7 |
| Cost of Revenue | |||||
| Gross Profit | 124 | 128 | 103 | 13.9 | 40.3 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 362 | 521 | 248 | 100 | 109 |
| Operating Profit | -98.5 | -281 | -70.4 | -82.8 | -59 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -119 | -298 | -84.3 | -82.5 | -51.7 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -110 | -271 | -79.6 | -82.8 | -51.7 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -110 | -271 | -79.6 | -64.9 | -51.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -110 | -271 | -79.6 | -64.9 | -51.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.926 | -1.65 | -0.539 | -1.16 | -0.458 |